| Assessment Status |
NCPE assessment ongoing |
| HTA ID |
22044 |
| Drug |
Tisagenlecleucel |
| Brand |
Kymriah® |
| Indication |
For the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. |
| Rapid review commissioned |
28/06/2022 |
| Rapid review completed |
27/07/2022 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tisagenlecleucel compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
31/08/2022 |
| Pre-submission consultation with Applicant |
06/12/2022 |
| Full submission received from Applicant |
14/07/2023 |
| Preliminary review sent to Applicant |
06/02/2024 |
| NCPE assessment re-commenced |
08/03/2024 |
| Follow-up to preliminary review sent to Applicant |
11/04/2024 |
| NCPE assessment re-commenced |
18/04/2024 |
